Literature DB >> 16543149

The molecular basis of vitamin D receptor and beta-catenin crossregulation.

Salimuddin Shah1, Md Naimul Islam, Sivanesan Dakshanamurthy, Imran Rizvi, Mahadev Rao, Roger Herrell, Glendon Zinser, Meggan Valrance, Ana Aranda, Dino Moras, Anthony Norman, JoEllen Welsh, Stephen W Byers.   

Abstract

The signaling/oncogenic activity of beta-catenin can be repressed by activation of the vitamin D receptor (VDR). Conversely, high levels of beta-catenin can potentiate the transcriptional activity of 1,25-dihydroxyvitamin D3 (1,25D). We show here that the effects of beta-catenin on VDR activity are due to interaction between the activator function-2 (AF-2) domain of the VDR and C terminus of beta-catenin. Acetylation of the beta-catenin C terminus differentially regulates its ability to activate TCF or VDR-regulated promoters. Mutation of a specific residue in the AF-2 domain, which renders the VDR trancriptionally inactive in the context of classical coactivators, still allows interaction with beta-catenin and ligand-dependent activation of VDRE-containing promoters. VDR antagonists, which block the VDRE-directed activity of the VDR and recruitment of classical coactivators, do allow VDR to interact with beta-catenin, which suggests that these and perhaps other ligands would permit those functions of the VDR that involve beta-catenin interaction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16543149     DOI: 10.1016/j.molcel.2006.01.037

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  102 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 2.  Vitamin D: roles in renal and cardiovascular protection.

Authors:  Yan C Li
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

3.  The vitamin D receptor: a tumor suppressor in skin.

Authors:  Daniel David Bikle
Journal:  Discov Med       Date:  2011-01       Impact factor: 2.970

4.  Discovery of novel vitamin D receptor interacting proteins that modulate 1,25-dihydroxyvitamin D3 signaling.

Authors:  Pamela A Marshall; Zachary Hernandez; Ichiro Kaneko; Tim Widener; Christa Tabacaru; Izayadeth Aguayo; Peter W Jurutka
Journal:  J Steroid Biochem Mol Biol       Date:  2012-05-14       Impact factor: 4.292

5.  1, 25(OH)₂D₃ inhibits hepatocellular carcinoma development through reducing secretion of inflammatory cytokines from immunocytes.

Authors:  Jian Guo; Zhenhua Ma; Qingyong Ma; Zheng Wu; Ping Fan; Xiaojie Zhou; Lulu Chen; Shuang Zhou; David Goltzman; Dengshun Miao; Erxi Wu
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 6.  Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting.

Authors:  William Hankey; Wendy L Frankel; Joanna Groden
Journal:  Cancer Metastasis Rev       Date:  2018-03       Impact factor: 9.264

7.  Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.

Authors:  Weichun He; Young Sun Kang; Chunsun Dai; Youhua Liu
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

Review 8.  Vitamin D and differentiation in cancer.

Authors:  Elzbieta Gocek; George P Studzinski
Journal:  Crit Rev Clin Lab Sci       Date:  2009       Impact factor: 6.250

Review 9.  WNT signalling pathways as therapeutic targets in cancer.

Authors:  Jamie N Anastas; Randall T Moon
Journal:  Nat Rev Cancer       Date:  2013-01       Impact factor: 60.716

Review 10.  Nonclassic actions of vitamin D.

Authors:  Daniel Bikle
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.